A 'clickable' disaccharide was prepared by treating the aldehyde precursor with hydroxylamine, followed by the catalytic hydrogenation and diazotransfer reaction. This disaccharide was successfully applied to the elongation of the backbone construction of ultralow molecular weight (ULMW) heparins using two bacterial glycosyl transferases, N-acetyl glucosaminyl transferase from Escherichia coli K5 (KfiA) and heparosan synthase-2 (pmHS2) from Pasteurella multocida.
Introduction
Heparan sulfate (HS) and heparin are linear, highly sulfated, anionic polysaccharides that belong to the glycosaminoglycan (GAG) family. 1 These GAGs are composed of a repeating disaccharide motif of a glucuronic acid (GlcA) or an iduronic acid (IdoA) residue and a glucosamine residue, including N-acetylglucosamine (GlcNAc), N-sulfoglucosamine (GlcNS), or N-unsubstituted glucosamine (GlcNH 2 ). 2 HS is an abundant GAG on the surface of mammalian cells and in the extracellular matrix. It plays regulatory roles in several pathophysiological processes, such as development, angiogenesis, blood coagulation, and tumor metastasis. [3] [4] [5] Preparation of pure GAG oligosaccharides is a major challenge for carbohydrate chemists [6] [7] [8] because traditional chemical synthesis of structurally defined GAGs relies on the efficient introduction of protecting groups, epimerization of GlcA to IdoA, stereoselective glycosylation, the efficient removal of protecting groups, and sulfonation, requiring a large number of synthetic steps to furnish the product. [9] [10] [11] The biosynthesis of GAGs in the Golgi of eukaryotic cells suggests a more efficient enzymatic route, which includes the building of the polysaccharide backbone, as well as introducing sulfo groups and IdoA residues. 12, 13 Employing a chemoenzymatic approach in our previous work, we successfully synthesized the ULMW heparin heptasaccharides with 10 and 12 steps in 45% and 37% overall yields based on the disaccharide acceptor degraded from heparosan ( Fig. 1) , which showed very similar binding affinities and in vitro anti-Xa activities comparing with the commercial drug Arixtra. 14, 15 The chemoenzymatic synthesis of structurally defined heparin oligosaccharide glycoconjugates or immobilized heparin oligosaccharides might be accomplished through the introduction of a reactive site into the heparin oligosaccharide. A heparin oligosaccharide backbone can be elongated on a disaccharide acceptor to achieve this goal. 16 We report the synthesis of a disaccharide acceptor with an azido group as a reactive site at the reducing end (Fig. 1) . This disaccharide acceptor can be applied to a 'click' reaction or released as a free amine group for diverse conjugation. This modified disaccharide is quite suitable for use as an extendable acceptor for the backbone elongation for the construction of ultralow molecular weight (ULMW) heparins.
Results and discussion
Heparosan-(?4)-GlcA-(1?4)-GlcNAc-(1?) n 17 has been prepared from the Escherichia coli K5 strain 18 and isolated at kilogram scale and was employed as starting material for our disaccharide acceptor target (Scheme 1). Heparosan was dissolved in 2 M NaOH solution under 60°C for 24 h to obtain the N-deacetylated heparosan polysaccharide according to previously described methods. 19, 20 The N-deacetylated heparosan polysaccharide was deaminated with nitrous acid at low pH ($4.5), and neutralized with 2 M NaOH to furnish disaccharide 4-(GlcA-(1?4) anhydromannose (AnMan)). 21, 22 We found that the free aldehyde group at the reducing end of disaccharide 4 was primarily obtained as the hydrate form, hemiacetal 5. Hemiacetal 5 was identified by its 1 H NMR and mass spectrum, which showed the disappearance of the characteristic aldehyde peak, at $9 ppm, and displayed the hydrate form
The b-configuration of the glycosidic linkage was confirmed on the basis of the 7.8 Hz J 1,2 coupling constant, which indicates that the H-1 II and H-2 II atoms are in a trans relationship to one another. 23 Reductive amination of 5 was initially attempted with sodium cyanoborohydride, however, low yields were achieved using both aliphatic and aromatic amines. Treatment of 5 with hydroxylamine in aqueous sodium acetate solution gave significantly improved yields ($90%), resulting in the formation of oxime 6 as a mixture of the E and Z isomers. 24 After the size exclusion chromatography, the 1 H NMR spectrum of oxime 6 showed doublets at 7.44 (J = 3.78 Hz) and 6.84 (J = 6.88 Hz) corresponding to the presence of the CH@N group in an (E)-oxime to (Z)-oxime ratio of 7:2.
Reduction of oxime 6 was carried out smoothly employing hydrogen with Pd(OH) 2 /C catalyst affording the corresponding amino derivative 7 in 91% yield. The structure of 7 was confirmed by 1 H and 2D NMR spectroscopy as it showed the disappearance of the CH@N proton and the appearance of a multiplet at $3.6 ppm, attributable to a newly formed CH 2 group. Conversion of the amino group to an azido group was subsequently accomplished by treating 7 with sodium azide, Tf 2 The 13 C NMR spectrum of compound 1 showed that C-1 I shifted to 51.4 ppm, corresponding to a CH 2 group after introducing an azido group at the reducing end. Compound 1, an azido-functional acceptor, could be employed to construct heparin oligosaccharide backbones. However, this disaccharide acceptor always contained some impurities that were difficult to remove by the size exclusion chromatography when performing large-scale reactions. Consequently, we protected the carboxyl group with a methyl ester in 95% yield under acidic conditions and the free hydroxyl groups as acetyl esters in quantitative yield to obtain compound 8, which was easily purified on a silica column. Compound 8 was then quantitatively deprotected by treating with 2 M NaOH and desalted to obtain pure disaccharide acceptor 1.
Next, the heparin oligosaccharide backbone was prepared by enzymatic glycosylation of disaccharide acceptor 1 (Scheme 2). Disaccharide 1 (GlcA-AnMan-N 3 ) was incubated overnight with UDP-GlcNTFA and KfiA at room temperature to furnish the trisaccharide product. Reverse-phase ion-pairing HPLC (RPIP-HPLC) was employed to monitor the generation of uridine diphosphate (UDP). Here, we employed an unnatural UDP-GlcNTFA donor, as it can be readily converted to an N-sulfoglucosamine residue in a subsequent step.
14 Afterward, one equivalent of UDP-GlcA was added into the above mixture and incubated for 4-5 h in the presence of pmHS2, followed by the addition of a second equivalent of UDP-GlcA and additional pmHS2 to ensure reaction completion. The resulting tetrasaccharide 9 was recovered by size exclusion chromatography. The structures of the trisaccharide intermediate and tetrasaccharide 9 were both confirmed by HR ESI-MS and NMR spectroscopy.
Conclusions
We have developed a practical route including acidic depolymerization, oximation, hydrogenation and diazotransfer reaction, toward the large scale preparation of the N 3 -containing 'clickable' acceptor, which was also successfully applied on the backbone construction of ultralow molecular weight (ULMW) heparin oligosaccharide employing the enzymatic glycosylation. Further elongation and sulfonation of this tetrasaccharide acceptor is ongoing. 
N-deacetylation of heparosan (3)
Heparosan 2 (3.3 g, 0.22 mmol) dissolved in 2 M NaOH (165 mL) was heated at 60°C until the solution is clear. After stirring for another 24 h under an argon atmosphere at 60°C, the solution was dialyzed with 1000 molecular weight cutoff (MWCO) dialysis membrane against double-distilled water for 24 h. Then, the dialysate was lyophilized to give the N-deactylated heparosan (3) as a yellow powder. Spectra were in agreement with reported data. Pd(OH) 2 -C 10% (0.19 g) was added to a solution of oxime 6 (240 mg, 0.68 mmol) in water and several drops of acetic acid were subsequently added. The suspension was stirred under H 2 at atmospheric pressure and room temperature for 2 h. The solvent was removed under reduced pressure and the resulting syrup was purified by a Biogel P-2 column (1.5 Â 200 cm)at a flow rate of 15 mL/h to obtain compound 7 (210 mg, 0.62 mmol, 91%) as a white powder (BuOH/HCOOH/H 2 O = 4:8:1, R f = 0.28). 
